Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Merck delivered a home run with its Phase 3 HYPERION trial, showcasing WINREVAIR’s prowess in battling pulmonary arterial ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

The projection represents a negative annual growth rate of 0.08%. The total number of diagnosed prevalent cases of pulmonary ...

A comprehensive new study from the Centers for Disease Control and Prevention’s National Center for Health Statistics shows that chronic health conditions are nearly universal among Americans age 85 ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 ...

With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Patients with pulmonary hypertension associated with congenital heart disease make up an increasing proportion of the total pulmonary hypertension population who bring with them added complexity ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...